Please login to the form below
CHMP names France's Pierre Demolis vice-chair
He is director of the oncology and haematology division at the ANSM
The European Medicines Agency (EMA) has appointed France's Dr Pierre Demolis as vice-chair of the Committee for Medicinal Products for Human Use (CHMP).
Dr Demolis is director of the oncology and haematology division at the French Medicines Agency (ANSM) and originally trained as a cardiologist.
In his new role, he will work with chair Dr Tomas Salmonson of Sweden to head the CHMP, which provides recommendations on the use of drugs in the EU.
Dr Demolis' appointment comes after six years serving as a member of the CHMP. He has prior experience at the EMA, including serving as a member of the Scientific Advisory Working Group.
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
